To investigate whether MENi could also target tumour-intrinsic PRC2 dependence, we evaluated the effects of VTP50469 on the survival of diffuse large B-cell lymphoma (DLBCL) cell lines harbouring gain-of-function mutations in EZH2. Here, EZH2 is linked to neoplasm.